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At Risk for Huntington's Disease
HD is a genetically caused brain disorder that causes uncontrollable bodily movements and robs
people's ability to walk, talk, eat, and think. The final result is a slow, ugly death. Children of parents
with HD have a 50-50 chance of inheriting the disease. There is no cure or treatment.
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MONDAY, OCTOBER 19, 2015

Huntington’s disease patients get first dosing in
historic Isis Pharmaceuticals’ gene-silencing drug
trial
Huntington’s disease patients in England have received the first dosing of
an Isis Pharmaceuticals drug, ISIS-HTTRx, aimed at stopping the disease
at its genetic roots.
The patients displayed no immediate complications. This so far confirms
expectations that the gene-silencing drug would be safe to use, although
clinical trial administrators will continue to make critical observations in
the coming months. Other dosings will occur. The drug’s efficacy will not
be analyzed until later stages of the trial.
An announcement came October 19 that a small number of Phase I clinical
trial participants at University College London (UCL), the lead site for
study, had received injections via spinal cord of the Isis compound,
according to a UCL news release.
“It's the beginning of quite an important journey in Huntington's disease,”
Sarah Tabrizi, Ph.D., the director of UCL’s Huntington's Disease Centre
and the global chief clinical investigator for the trial, told the BBC. “It is
clearly very early but this is a step forward.
“The preclinical work shows that if you lower production of the mutant
protein then animals recover a large amount of motor function.
Huntington's is a really terrible disease that blights families. I know a
mother whose husband and three children were affected. This would have
a massive impact [if it works].”
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Sarah Tabrizi, Ph.D. (photo from University College London website)
Slowing or preventing the disease
The news comes just three months after Isis announced the official start of
the trial, the first time HD patients are receiving a substance aimed to
attack the genetic causes of the disease. Isis has partnered with the Swissbased pharmaceutical giant Roche to facilitate the clinical trial and, if it’s
successful, the marketing of the drug.
Isis officials were unavailable for comment on October 19 but the main
scientist spearheading the development of ISIS-HTTRx, which signifies a
medication for HD, commented in the UCL release.
“We designed ISIS-HTTRx to target the huntingtin gene and reduce the
production of huntingtin protein, which is the known cause of the disease,”
stated Frank Bennett, Ph.D., the Isis senior vice president for research.
“This approach has the potential to prevent or slow the progression of this
disease. If this first-in-human trial proves the drug is safe, we look forward
to continuing our successful partnership with Roche to bring the drug to
market.”
Dr. Bennett has previously described the drug, scientifically known as an
antisense oligonucleotide (oligo), as a “laser-guided missile” targeting a
“specific messenger RNA that causes a particular disease and kill it or take
it out of the body so that you don’t produce that messenger RNA.”
Isis announced the details of the trial in August 2014 (click here to read
more).
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Frank Bennett, Ph.D., senior vice president for research at Isis
Pharmaceuticals (photo by Dr. Ed Wild)
Safety and tolerability first
The Phase I trial involves patients at UCL and also at various sites in
Canada and Germany. Across all sites, a total of about 36 patients will take
part. Phase I trials focus primarily on the safety and tolerability of a drug.
The study will also help determine the frequency and size of dosages for
eventual Phase II and Phase III trials, which measure efficacy.
All of the volunteers have early stage HD. Because of the use of spinal taps
to administer the drug and the highly experimental nature of the oligos, no
non-HD-affected individuals are taking part as controls.
No announcements have yet been made about dosing of patients in Canada
and Germany.
According to the UCL release, the ISIS-HTTRx is taking place in the new
Leonard Wolfson Experimental Neurology Centre, a custom-built facility
designed to accelerate innovative treatments for neurodegenerative
diseases.
“The administration of the first doses of ISIS-HTTRx marks the Centre's
first use as a phase 1 'first into human' trial facility, as well as the first time
that an experimental drug has been given by spinal injection in the 156year history of the National Hospital for Neurology and Neurosurgery, part
of University College London Hospitals (UCLH) NHS Foundation Trust,”
the release stated.
What’s next?
“The first volunteers have been treated without any immediate
complications,” the scientist-written HD research site HDBuzz observed.
“The next year or so will be a period of intense study of these trial
volunteers to make sure that they don’t have unexpected complications
from the treatment. They’ll also be examined for a range of measures of
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whether or not the drug is working, which will provide critical information
for planning future HD gene silencing studies.”
Depending on the pace of recruitment, Phase I most likely will end in 2017.
If Phase I is successful, Phase II could follow no sooner than nine months
later. All three phases of a clinical trial program typically take at least five
years.
Historically, only ten percent of clinical trials ever result in a marketable
drug.
Regardless, the HD community has crossed a significant threshold.
Science has yet to produce an effective treatment for HD, as well as for
Alzheimer’s, Parkinson’s, and other neurological disorders. HD could be
the first.
Hope is palpable.
As a carrier of the deadly HD gene who lost his mother to the disease in
2006 and has tracked the Isis project since 2007, I am thrilled that our
fellow HD community members have successfully made the first step in
this historic clinical trial. They deserve our enthusiastic applause for
volunteering.
(Disclosure: I hold a symbolic amount of Isis shares.)
Posted by Gene Veritas at 9:15 PM
Labels: antisense oligonucleotide , clinical trials , Frank Bennett , gene-silencing ,
Huntington's disease , Isis Pharmaceuticals , ISIS-HTTRx , Sarah Tabrizi , treatments

3 comments:
Ricki Lewis said...
If the drug targets messenger RNA, that is not the genetic roots.
That would be DNA. The expanded repeat Htt in the DNA is
still there, and extra long mRNAs will still be transcribed in the
absence of the drug. As I posted on Facebook, the fact that
there is a trial is indeed great news. But partial information can
raise expectations.
The cystic fibrosis drug Kalydeco, enormously successful, is
also described as halting that disease at its roots. Kalydeco
affects the protein conformation.
DNA encodes RNA, which encodes protein. Targeting anything
other than DNA is NOT targeting the roots of a disease.
Semantics maybe, but mechanisms are quite different, as are
long term effects. Gene therapy and perhaps someday gene
correction/editing using CRISPR/cas-9 would be attacking a
disease at its roots.
5:39 AM, October 20, 2015

Anonymous said...
I wish I could hug and personally thank all 36 of the volunteers
for this early phase of the clinical trial. I hope, hope, hope that
they will all be safe and that the intervention will prove to be
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effective.
Beverly Peterson
9:23 AM, October 24, 2015

WonkaVater said...
That is encouraging news, Gene. Thanks for sharing. Keeping
the faith and praying for the 10% miracle (on an effective drug
coming out of phase I, II, and III). Let's do this!!!
4:15 PM, October 26, 2015
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